SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
公司代碼SIGA
公司名稱SIGA Technologies Inc
上市日期Sep 09, 1997
CEONguyen (Diem)
員工數量46
證券類型Ordinary Share
年結日Sep 09
公司地址31 East 62Nd Street
城市NEW YORK
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編10065
電話12126729100
網址https://www.siga.com/
公司代碼SIGA
上市日期Sep 09, 1997
CEONguyen (Diem)